Merck resolves Vytorin case for $688m


Merck & Co has agreed to pay $688 million (£445 million) to settle claims that it failed to report clinical trial data relating to cholesterol brands Zocor (simvastatin) and Vytorin (ezetimibe, simvastatin).

The case against the company was brought by a group of disgruntled investors, who claim Merck unfairly withheld negative information about the brands for a year.

In March 2008, Merck and Schering-Plough – which later merged under the Merck banner – published results of a key Vytorin trial that showed the drug did not work as well as expected. In the immediate aftermath, the share prices for the two dropped sharply. But the investors claim that the two companies knew that the trial was a flop at least a year before that.

The company will now pay $215 million to resolve the case against Merck and $473 million to resolve the case against Schering-Plough. However, it made no admission of wrongdoing and says that both companies acted responsibly in relation to the trial.


Related Content

Business roundup

27 January 2009 Business

news image

Industry news, February 2009

Business roundup

28 April 2008 Business

news image

Industry news

Most Read

(–)-Jiadifenolide

27 July 2015 Organic Matter

news image

BRSM wonders what makes a route so good it becomes the last total synthesis of a complex target

Weaving is believing

23 July 2015 The Crucible

news image

Philip Ball unpicks the history of science’s woollen wardrobe

Most Commented

Scientist imprisoned over fraudulent HIV vaccine research

6 July 2015 News and Analysis

news image

Former Iowa State University researcher gets four-and-a-half years in prison for faking vaccine research funded by the NIH

Single polymer pill could deliver entire drug course in one go

27 July 2015 Research

news image

Flexible elastomer ring springs open to stay in stomach and could slowly release drugs over days